This test may exhibit interference when sample is collected from a person who is consuming a supplement with a high dose of biotin (also termed as vitamin B7 or B8, vitamin H, or coenzyme R).

It is recommended to ask all patients who may be indicated for this test about biotin supplementation. Patients should be cautioned to stop biotin consumption at least 72 hours prior to the collection of a sample.

Gold serum separator (SST) tube

Immediatley following collection, mix sample by gently inverting 5 times

1. Allow sample to clot for a minimum of 30 minutes
2. Spin within two (2) hours of sample collection

Gold serum separator (SST) tube

Red serum vial/tube, 5 mL

1. Allow sample to clot
2. Spin within two (2) hours of sample collection
3. Transfer serum to a Transfer vial/tube with cap - 12mL (LabCorp), labelled as serum

Transfer vial/tube with cap - 12mL (LabCorp)

Refrigerated (preferred) - 6 days

Frozen - 12 months

Freeze/thaw cycles - stable x1

• Citrate plasma specimen
• Samples collected in heparin or from patients on heparin therapy
• Lipemic samples
• Hemolyzed samples
• Improper labeling

Electrochemiluminescence Immunoassay (ECLIA)

0.0 - 1.75 units/L

Thyrotropin-receptor antibody is an autoantibody to the thyroid cell receptor for thyroid-stimulating hormone. It can be demonstrated in 90% of patients with Graves' disease, and is the cause of the hyperthyroidism of that condition. The characterization of TRA resolved much confusion about long-acting thyroid stimulator (LATS) and LATS protector, which are both, in fact, thyroid-stimulating autoantibodies which simply behaved differently in animal test systems. These antibodies are present in 50% of euthyroid Graves' disease as well as hyperthyroid patients. They play a major role in the pathogenesis of Graves' disease. Detection of these antibodies is useful in prediction of neonatalhyperthyroidism and prediction of relapse of hyperthyroidism.